Focus Issue: Cardiometabolic RiskQuantifying Cardiometabolic RiskFriedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications
Key Words
Abbreviations and Acronyms
Cited by (0)
Atherotech provided the investigators with de-identified data generated from commercial lipid analyses. This was an investigator-initiated study and Atherotech did not provide payments for the research or writing of the manuscript. Atherotech did not participate in the analysis of the data or influence the conclusions. Dr. Brinton is on the medical advisory board for Atherotech, Inc.; has received compensation for consultancy and lecturers from Abbott Laboratories, AstraZeneca, Merck & Co., Bristol-Myers Squibb, Daiichi Sankyo Inc., Kaneka Pharma America, Takeda Pharmaceuticals, Kowa Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, LipoScience Inc., Amarin Pharmaceuticals, Health Diagnostics Laboratory, Roche/Genentech, Essentialis, Arisaph; and has received research grants from Abbott Laboratories, Merck & Co., Amarin Pharmaceuticals, Health Diagnostics Laboratory, and Roche/Genentech. Dr. Toth is on the medical advisory board for Atherotech, Inc.; has received compensation for consultancy and lecturers from Abbott Laboratories, Aegerion, Amgen, Amylin, AstraZeneca, GlaxoSmithKline, Kowa, and Merck & Co. Dr. Kulkarni is the Atherotech Diagnostics Lab Research Director; and receives royalty from the University of Alabama in Birmingham. Dr. Mize was an employee of Atherotech Diagnostics Lab during this study. Dr. Kwiterovich received compensation for consultancy from Merck & Co; and research grants from Pfizer. Dr. DeFilippis is a compensated study adjudicator for Radiometer. Dr. Jones is on the medical advisory board for Atherotech, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.